MCID: RCT021
MIFTS: 54

Rectum Cancer

Categories: Cancer diseases, Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Rectum Cancer

MalaCards integrated aliases for Rectum Cancer:

Name: Rectum Cancer 11 14 16
Malignant Neoplasm of Rectum 11 31
Rectal Cancer 11 53
Malignant Tumor of Rectum 11
Carcinoma of the Rectum 11
Malignant Rectal Tumor 11
Malignant Rectum Tumor 11
Carcinoma of Rectum 11
Cancer of Rectum 11
Rectal Carcinoma 53
Rectal Cancers 14
Cancer, Rectal 38

Classifications:



External Ids:

Disease Ontology 11 DOID:1993
ICD9CM 34 154.1
MeSH 43 D012004
NCIt 49 C7418 C9382
SNOMED-CT 68 254582000 93984006
ICD10 31 C20
UMLS 71 C0007113 C0949022

Summaries for Rectum Cancer

Disease Ontology: 11 A colorectal cancer that is located in the rectum.

MalaCards based summary: Rectum Cancer, also known as malignant neoplasm of rectum, is related to rectosigmoid junction neoplasm and familial colorectal cancer. An important gene associated with Rectum Cancer is CEACAM5 (CEA Cell Adhesion Molecule 5), and among its related pathways/superpathways are Endometrial cancer and Base excision repair. The drugs Tramadol and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include rectum, lymph node and colon, and related phenotypes are neoplasm and digestive/alimentary

Related Diseases for Rectum Cancer

Diseases in the Rectum Cancer family:

Rectum Carcinoma in Situ

Diseases related to Rectum Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1041)
# Related Disease Score Top Affiliating Genes
1 rectosigmoid junction neoplasm 32.5 MLH1 KRT20 KRAS CEACAM5
2 familial colorectal cancer 32.3 MUTYH MSH2 MLH1
3 rectum adenocarcinoma 32.1 MSH6 MSH2 MLH1 MIR215 KRT20 KRAS
4 colorectal cancer 31.6 TYMS TYMP MUTYH MSH6 MSH2 MMP7
5 familial adenomatous polyposis 31.4 MUTYH MSH6 MSH2 MLH1 KRAS APC
6 rectal benign neoplasm 31.2 TYMS MSH6 MSH2 MLH1 MIR31 MIR1909
7 adenosquamous carcinoma 31.2 KRT20 KRAS CEACAM7 CEACAM5
8 peripheral nervous system disease 31.2 MIR31 MIR21 MIR17 MIR145 KRAS
9 lynch syndrome 31.2 TYMS MUTYH MSH6 MSH2 MLH1 MIR31
10 papilloma 31.1 TYMS KRT20 KRAS CDKN1A
11 appendix adenocarcinoma 31.1 MSH6 KRT20 KRAS CEACAM5
12 diffuse gastric cancer 31.1 MUTYH MSH6 MSH2 MLH1 KRAS
13 lynch syndrome 1 31.1 MSH6 MSH2 MLH1
14 mucinous adenocarcinoma 31.0 MSH6 MSH2 MLH1 KRT20 KRAS CEACAM5
15 mismatch repair cancer syndrome 1 31.0 MSH6 MSH2 MLH1 APC
16 signet ring cell adenocarcinoma 31.0 MSH6 MSH2 MLH1 KRT20 KRAS CEACAM5
17 cholangiocarcinoma 30.9 MMP7 MIR21 KRT20 KRAS CEACAM5
18 dihydropyrimidine dehydrogenase deficiency 30.9 TYMS TYMP DPYD
19 hemorrhoid 30.9 KRT20 CEACAM5 APC
20 linitis plastica 30.9 KRT20 CEACAM5
21 transitional cell carcinoma 30.8 MSH2 MLH1 KRT20 CDKN1A
22 colitis 30.8 MSH6 MSH2 MLH1 MIR21
23 gastrointestinal system disease 30.8 MIR31 MIR215 MIR21 MIR17 MIR145 APC
24 colonic benign neoplasm 30.8 MUTYH MSH6 MSH2 MMP7 MLH1 MIR21
25 human papillomavirus infectious disease 30.8 MIR31 MIR21 CDKN1A
26 rectum signet ring adenocarcinoma 30.7 MSH2 MLH1 CEACAM5
27 cervical cancer 30.7 TYMP MIR31 MIR21 MIR17 CDKN1A
28 intrahepatic cholangiocarcinoma 30.7 MIR17 KRAS CEACAM5
29 mismatch repair cancer syndrome 30.7 MUTYH MSH6 MSH2 MLH1 KRAS
30 bladder cancer 30.7 TYMS TYMP MSH2 MLH1 MIR31 MIR21
31 head and neck cancer 30.7 MIR31 MIR21 MIR17 MIR145 KRAS APC
32 teratoma 30.6 KRT20 KRAS CEACAM5
33 papillary adenocarcinoma 30.6 MIR21 KRAS CEACAM5
34 endometrial adenocarcinoma 30.6 MSH6 MSH2 MLH1 KRAS
35 esophageal cancer 30.6 TYMS TYMP MMP7 MLH1 MIR31 MIR21
36 adenoma 30.6 MUTYH MSH6 MSH2 MMP7 MLH1 KRT20
37 transverse colon cancer 30.6 MLH1 KRT20 KRAS CEACAM5
38 pseudomyxoma peritonei 30.6 KRT20 KRAS CEACAM5
39 colorectal adenoma 30.6 MUTYH MSH6 MSH2 MLH1 MIR31 MIR21
40 juvenile polyposis syndrome 30.6 MUTYH MSH6 MSH2 MLH1 APC
41 hepatocellular carcinoma 30.6 TYMS TYMP MSH2 MMP7 MLH1 MIR31
42 endometrial cancer 30.6 TYMP MUTYH MSH6 MSH2 MMP7 MLH1
43 rectosigmoid cancer 30.6 MUTYH MSH6 MSH2 MLH1 KRAS CEACAM5
44 inherited cancer-predisposing syndrome 30.6 MUTYH MSH6 MSH2 MLH1 APC
45 bap1 tumor predisposition syndrome 30.6 MUTYH MSH6 MSH2 MLH1 APC
46 large cell carcinoma 30.6 MIR31 MIR17 MIR145 KRT20 KRAS CEACAM5
47 colorectal adenocarcinoma 30.6 MSH6 MSH2 MLH1 MIR31 MIR17 MIR145
48 desmoid tumor 30.5 MUTYH MSH6 MSH2 APC
49 neurofibromatosis, type i 30.5 MSH6 MSH2 MLH1 KRAS
50 neurofibromatosis 30.5 MSH6 MSH2 MLH1 KRAS

Graphical network of the top 20 diseases related to Rectum Cancer:



Diseases related to Rectum Cancer

Symptoms & Phenotypes for Rectum Cancer

MGI Mouse Phenotypes related to Rectum Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.65 APC CDKN1A CEACAM5 KRAS MIR31 MLH1
2 digestive/alimentary MP:0005381 9.23 APC CDKN1A CEACAM5 DPYD KRAS MLH1

Drugs & Therapeutics for Rectum Cancer

Drugs for Rectum Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 451)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
4
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
5
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
6
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
7
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
8
Orphenadrine Approved Phase 4 83-98-7 4601
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
11
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
12
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
13
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523 135413547
14
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
15
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
16
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
17
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
18
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
19 Parasympatholytics Phase 4
20 Acetaminophen, hydrocodone drug combination Phase 4
21
Ketorolac Tromethamine Phase 4
22 Antiparkinson Agents Phase 4
23 Excitatory Amino Acid Antagonists Phase 4
24 Anesthetics, Dissociative Phase 4
25 Antitussive Agents Phase 4
26 Muscarinic Antagonists Phase 4
27 Cholinergic Antagonists Phase 4
28 Analgesics, Opioid Phase 4
29 Narcotics Phase 4
30 Adrenergic Agents Phase 4
31 Phosphodiesterase 5 Inhibitors Phase 4
32 Citrate Phase 4
33 Adrenergic alpha-Agonists Phase 4
34 Adrenergic Agonists Phase 4
35 Anesthetics, Local Phase 4
36 Anesthetics, Intravenous Phase 4
37 Anesthetics, General Phase 4
38 Anesthetics Phase 4
39 Hypnotics and Sedatives Phase 4
40 Anesthetics, Inhalation Phase 4
41
Etodolac Approved, Investigational, Vet_approved Phase 3 41340-25-4 3308
42
Propranolol Approved, Investigational Phase 3 318-98-9, 525-66-6 62882 4946
43
Minocycline Approved, Investigational Phase 3 10118-90-8, 13614-98-7 54675783 5281021
44
Cobalt Approved, Experimental, Withdrawn Phase 3 7440-48-4 104729
45
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
46
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
47
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 3 14769-73-4 26879
48
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
49
Lanreotide Approved Phase 3 108736-35-2 71349 6918011
50
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953

Interventional clinical trials:

(show top 50) (show all 1460)
# Name Status NCT ID Phase Drugs
1 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial. Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
2 A Non-randomised Controlled Trial of Early Intervention to Preserve Erectile Function After Laparoscopic Resection for Rectal Cancer Completed NCT01912586 Phase 4
3 The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer Completed NCT01421940 Phase 4 Placebo drug;Udenafil
4 Prospective Randomized Study of Single Incision Laparoscopic Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer Completed NCT01579721 Phase 4
5 Assessment of the Effect of Dexmedetomidine in the Management of Postoperative Pain When Combined With Fentanyl in the Patient-controlled Analgesia Completed NCT01373021 Phase 4 Fentanyl;Dexmedetomidine
6 Total Neoadjuvant Therapy in Rectal Cancer Treatment Recruiting NCT04747951 Phase 4 consolidation chemotherapy;adjuvant chemotherapy
7 A Randomized, Open-label Study to Compare Propofol Anesthesia With Sevoflurane Anesthesia in Terms of Overall Survival in Patients With Surgical Intervention for Either Breast-, Colon- or Rectal Cancer Recruiting NCT01975064 Phase 4 Propofol;Sevoflurane
8 Neoadjuvant Chemoradiation With Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer: A Real-Word Multi-center Study Recruiting NCT05148767 Phase 4 Neoadjuvant chemoradiotherapy based on irinotecan
9 Spinal Analgesia for Laparoscopic Abdominoperineal Rectal Amputation Using an Enhanced Recovery After Surgery Program: a Randomized Double-blind Placebo-controlled Trial Recruiting NCT05406765 Phase 4 Bupivacaine Injection
10 Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Laparoscopic Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series Terminated NCT01706822 Phase 4
11 Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Rectal Anterior Resection for Rectal Cancer Patients Unknown status NCT01861678 Phase 3
12 A Comparison for Laparoscopically Assisted and Open Surgery for Advanced Rectal Cancer After Preoperative Chemoradiation- Randomized Prospective Trial Unknown status NCT00470951 Phase 3
13 Short-course Preoperative Radiotherapy With Consolidating Chemotherapy vs. Preoperative Chemoradiation in Patients With Unresectable Rectal Cancer: Phase III Study Unknown status NCT00833131 Phase 3
14 The Randomised Study of Preoperative Radiotherapy and Local Excision for Radiosensitive Rectal Cancer Unknown status NCT00738790 Phase 3
15 Anastomotic Leakage in Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer : A Prospective, Randomized, Controlled Study Unknown status NCT02770911 Phase 3
16 A Randomized Phase III Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer Unknown status NCT02605265 Phase 3 Capecitabine;Irinotecan;Oxaliplatin
17 A Randomized Trial Comparing Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer Unknown status NCT00154752 Phase 3
18 Randomized Controlled Trial Comparing the Bladder and Sexual Functions of Patients Who Undergo Laparoscopic and Robotic Assisted Resection for Rectal Cancer Unknown status NCT01130233 Phase 3
19 A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT) Unknown status NCT00601549 Phase 3
20 Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer Unknown status NCT00597311 Phase 3
21 A Phase III Randomised Study Of J-Pouch Coloanal Anastomosis Versus Side-To-End Coloanal Anastomosis After Preoperative Radiotherapy And Total Mesorectal Excision In Patients With Mid And Distal Rectal Cancer Unknown status NCT00070005 Phase 3
22 Two-Week COurse Versus Conventionally Fractionated Preoperative Chemoradiotherapy In Locally Advanced Rectal Cancer (TwoArc Trial): A Phase III Randomized Clinical Trial Unknown status NCT02484040 Phase 3 Two-week course of radiation
23 5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer Unknown status NCT00189657 Phase 3
24 Randomized Trial of Wide Mesorectal Excision Versus Total Mesorectal Excision for Mid Rectal Cancer Unknown status NCT00007930 Phase 3
25 A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Rectal Cancer. Unknown status NCT00297791 Phase 3
26 (MansTaTME) Trans-anal Versus Laparoscopic Total Mesorectal Excision for Mid and Low Rectal Cancer Unknown status NCT03242187 Phase 2, Phase 3
27 Perioperative β-adrenergic Blocker and a COX2 Inhibitor in Patients Undergoing Resection for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Postoperative Immune Perturbations. A Multicenter Randomized Prospective Trial. Unknown status NCT00888797 Phase 3 Propranolol and Etodolac
28 An Open Label, Randomized, Multi-center, Phase II/III Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy With Intensity-modified Radiation Therapy (IMRT) in Local Advanced Rectal Cancer Unknown status NCT01064999 Phase 2, Phase 3 Oxaliplatin;Capecitabine
29 A Trial to Assess Robot-assisted Surgery and Laparoscopy-assisted Surgery in Patients With Mid or Low Rectal Cancer Unknown status NCT01423214 Phase 3
30 A Phase II/III Randomized Controlled Study of Neoadjuvant FOLFOX6 Treatment With or Without Radiation Compared to 5-Fu Based Chemoradiation in Treating Patients With Resectable Rectal Cancer Unknown status NCT01211210 Phase 2, Phase 3 fluorouracil;fluorouracil, oxaliplatin
31 Resource-Sparing Curative Treatment for Rectal Cancer Unknown status NCT01459328 Phase 3
32 The Safety and Effect of Transanual Tube Placement in Low Anterior Resection (LAR) for Rectal Cancer to Prevent Anastomotic Leak: Randomized Control Trial Study Unknown status NCT02905968 Phase 2, Phase 3
33 Preoperative Hyperfractionated Radiotherapy Versus Combined Radiochemotherapy for Patients With Locally Advanced Rectal Cancer: a Phase III Randomized Trial. Unknown status NCT01814969 Phase 3
34 Investigation of the Value of ctDNA Analysis in the Diagnosis, Treatment, and Surveillance of Patients With Surgically Resectable Colorectal Cancer Unknown status NCT03038217 Phase 3 Capecitabine +/- Oxaliplatin
35 A Phase III, Randomized Study of Adjuvant Chemotherapy for Patients With Rectal Adenocarcinoma Who Achieved Suboptimal Response After Neoadjuvant Chemo-radiotherapy. Unknown status NCT01941979 Phase 3 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
36 INTEnsification Radiotherapy With Accelerated Fractionation or ChemoTherapy And Local Excision After 3D External Radio-chemotherapy Unknown status NCT01653301 Phase 3 XELAC RT;XELOX RT
37 A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (5-FU) Plus Bevacizumab Versus Leucovorin and 5-FU Plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma Unknown status NCT00337389 Phase 3 5- Fluorouracil (5-FU);bevacizumab (Avastin);Leucovorin;CoFactor (ANX-510)
38 A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in Increasing the Pathological Major Response Rate in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy Unknown status NCT01579591 Phase 3
39 Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study Unknown status NCT02907385 Phase 3
40 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium: A Multicenter, Randomized, Double-Blind Clinical Trail Unknown status NCT02928692 Phase 3 Minocycline;Placebo
41 A Clinical Trial Comparing Preoperative Radiation Therapy And Capecitabine With or Without Oxaliplatin With Preoperative Radiation Therapy And Continuous Intravenous Infusion Of 5-Fluorouracil With or Without Oxaliplatin In The Treatment Of Patients With Operable Carcinoma Of The Rectum Unknown status NCT00058474 Phase 3 capecitabine;fluorouracil;oxaliplatin
42 RANDOMIZED TRIAL OF CONCOMITANT PREOPERATIVE RADIO-CHEMOTHERAPY WITH OR WITHOUT POSTOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CARCINOMA Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
43 Cancer Prevention and Treatment Among African American Older Adults Completed NCT00509444 Phase 3
44 Prospective Randomized Study Comparing the Results of Digital Rectal Examination in the Supine and Lateral Decubitus Completed NCT01727388 Phase 3
45 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
46 A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
47 Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer Completed NCT00025337 Phase 3 oxaliplatin;leucovorin calcium;fluorouracil
48 Phase III Trial Comparing a 28 Day Schedule of Daily Oral 5-FU Plus Eniluracil to Protracted Intravenous Infusion in Previously Untreated Patients With Advanced Colorectal Cancer Completed NCT00003873 Phase 3 fluorouracil;eniluracil
49 Preoperative Chemoradiotherapy and Postoperative Chemotherapy With Capecitabine and Oxaplatin vs.Capecitabine Alone in Locally Advanced Rectal Cancer (PETACC-6) Completed NCT00766155 Phase 3 capecitabine;oxaliplatin
50 PILOT OBSERVATIONAL STUDY OF NEOADJUVANT 5 x 5 RADIOTHERAPY FOLLOWED BY TRANSANAL ENDOSCOPIC MICROSURGERY FOR T1-T2 EXTRAPERITONEAL RECTAL CANCER WITH CURATIVE INTENT Completed NCT02127645 Phase 3

Search NIH Clinical Center for Rectum Cancer

Genetic Tests for Rectum Cancer

Anatomical Context for Rectum Cancer

Organs/tissues related to Rectum Cancer:

FMA: Rectum
MalaCards : Lymph Node, Colon, Liver, T Cells, Prostate, Lung, Bone Marrow

Publications for Rectum Cancer

Articles related to Rectum Cancer:

(show top 50) (show all 32174)
# Title Authors PMID Year
1
Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. 53 62
20504250 2010
2
KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. 53 62
19913317 2010
3
Calcium, vitamin D, VDR genotypes, and epigenetic and genetic changes in rectal tumors. 53 62
20432164 2010
4
Survivin expression quantified by Image Pro-Plus compared with visual assessment. 53 62
19407655 2009
5
Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection. 53 62
19757443 2009
6
Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells. 53 62
19504123 2009
7
Microsatellite instability and survival in rectal cancer. 53 62
19669908 2009
8
Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer. 53 62
19593573 2009
9
Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor. 53 62
19832985 2009
10
Prognostic value of postoperative CEA clearance in rectal cancer patients with high preoperative CEA levels. 53 62
19657698 2009
11
[Prognosis of rectal cancer patients after total mesorectal excision]. 53 62
19728904 2009
12
High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. 53 62
19491899 2009
13
A simple scoring system based on clinical features to predict locally advanced rectal cancers. 53 62
19367434 2009
14
Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. 53 62
19101093 2009
15
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. 53 62
19436196 2009
16
Dihydropyrimidine dehydrogenase mRNA expression in peripheral blood of rectal cancer patients is significantly associated with residual tumor and distant metastases following resection. 53 62
19180589 2009
17
Radiation-induced thymidine phosphorylase upregulation in rectal cancer is mediated by tumor-associated macrophages by monocyte chemoattractant protein-1 from cancer cells. 53 62
19215821 2009
18
Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. 53 62
18619834 2009
19
Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. 53 62
18722050 2008
20
Significance of thymidine phosphorylase expression in stromal cells around invasive front of rectal cancer. 53 62
19260474 2008
21
Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. 53 62
18406888 2008
22
Importance of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase expression at the invasive front of T3 rectal cancer as prognostic factors. 53 62
18613375 2008
23
Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. 53 62
18286688 2008
24
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. 53 62
18087284 2008
25
Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. 53 62
17805549 2008
26
CDX2 VDR polymorphism and colorectal cancer. 53 62
18086783 2007
27
Germline mutations of the MYH gene in Korean patients with multiple colorectal adenomas. 53 62
17703316 2007
28
Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes. 53 62
17636402 2007
29
Carcinoembryonic antigen and patterns of recurrence after curative resection of the colorectal cancer. 53 62
18251140 2007
30
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. 53 62
17445998 2007
31
[Expression and clinical significance of matrilysin (MMP-7) in human rectal cancer]. 53 62
17718429 2007
32
Novel mutations and sequence variants in exons 3-9 of human T cell factor-4 gene in sporadic rectal cancer patients stratified by microsatellite instability. 53 62
17659738 2007
33
Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. 53 62
17387743 2007
34
Carcinoembryonic antigen (CEA) measurement during follow-up for rectal carcinoma is useful even if normal levels exist before surgery. A retrospective study of CEA values in the TME trial. 53 62
17174516 2007
35
[Fragile histidine triad protein expression and correlation with apoptosis in rectal carcinoma]. 53 62
17380463 2007
36
Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. 53 62
16896992 2007
37
Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma. 53 62
17688376 2007
38
Rectal cancer metastasis to the head of the pancreas treated with pancreaticoduodenectomy. 53 62
18040627 2007
39
Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas. 53 62
18334831 2007
40
[Quantification of PPARdelta mRNA by real-time RT-PCR in rectal cancer tissues]. 53 62
17294733 2007
41
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. 53 62
16971666 2006
42
[Influence and significance of preoperative intraarterial infusion chemotherapy combined with radiotherapy on survivin, p53 and Bax expression in low rectal carcinoma]. 53 62
17094914 2006
43
Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. 53 62
17241515 2006
44
The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery. 53 62
17016487 2006
45
Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. 53 62
16943525 2006
46
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy. 53 62
16931962 2006
47
Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. 53 62
16943523 2006
48
Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. 53 62
16741523 2006
49
Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. 53 62
16538413 2006
50
Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. 53 62
16686938 2006

Variations for Rectum Cancer

Copy number variations for Rectum Cancer from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 139647 2 185171337 185512459 Copy number ZNF804A Rectal cancer
2 166960 3 1109627 1420278 Copy number CNTN6 Rectal cancer
3 225401 7 45400000 54000000 Copy number EGFR Rectal cancer

Expression for Rectum Cancer

Search GEO for disease gene expression data for Rectum Cancer.

Pathways for Rectum Cancer

Pathways related to Rectum Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.35 MSH6 MSH2 MLH1 KRAS CDKN1A APC
2
Show member pathways
12.2 MUTYH MSH6 MSH2 MLH1
3 11.97 TYMS MUTYH MSH6 MSH2 MLH1 DPYD
4 11.84 MSH2 MLH1 CDKN1A APC
5 11.76 MMP7 KRAS CDKN1A
6 11.71 KRAS CDKN1A APC
7 11.62 TYMS MSH6 CDKN1A
8 11.6 MSH2 MLH1 MIR145 CDKN1A
9
Show member pathways
11.52 TYMS TYMP DPYD
10 11.38 MSH6 MSH2 MMP7 MLH1 KRAS CDKN1A
11 11.28 MIR21 MIR17 MIR145 CDKN1A
12 11.23 TYMP KRAS CDKN1A
13 11.04 MLH1 MSH2 MSH6

GO Terms for Rectum Cancer

Cellular components related to Rectum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 9.13 MSH2 MLH1
2 MutSalpha complex GO:0032301 8.92 MSH6 MSH2

Biological processes related to Rectum Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 10.08 MUTYH MSH6 MSH2 MLH1 CDKN1A APC
2 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.96 MSH6 MSH2 MLH1
3 isotype switching GO:0045190 9.88 MLH1 MSH2 MSH6
4 positive regulation of helicase activity GO:0051096 9.85 MSH6 MSH2
5 positive regulation of isotype switching to IgA isotypes GO:0048298 9.81 MSH2 MLH1
6 maintenance of DNA repeat elements GO:0043570 9.67 MSH6 MSH2
7 somatic hypermutation of immunoglobulin genes GO:0016446 9.63 MSH6 MSH2 MLH1
8 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.56 MIR31 MIR21 MIR17 MIR145
9 mismatch repair GO:0006298 9.56 MUTYH MSH6 MSH2 MLH1
10 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.54 MIR21 MIR17
11 pyrimidine nucleobase metabolic process GO:0006206 9.54 TYMS TYMP
12 positive regulation of metalloendopeptidase activity GO:1904685 9.52 MIR21 MIR17
13 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.5 MSH2 MLH1
14 negative regulation of interleukin-21 production GO:0032705 9.46 MIR215 MIR21
15 positive regulation of cellular response to hypoxia GO:1900039 9.43 MIR21 MIR145
16 somatic recombination of immunoglobulin gene segments GO:0016447 9.02 MSH6 MSH2 MLH1

Molecular functions related to Rectum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP-dependent DNA damage sensor activity GO:0140664 9.85 MSH6 MSH2 MLH1
2 mRNA 3'-UTR binding GO:0003730 9.78 MIR31 MIR21 MIR17 MIR145
3 MutSalpha complex binding GO:0032407 9.76 MUTYH MLH1
4 single guanine insertion binding GO:0032142 9.73 MSH6 MSH2
5 mRNA base-pairing translational repressor activity GO:1903231 9.72 MIR145 MIR17 MIR21 MIR215 MIR31
6 single thymine insertion binding GO:0032143 9.71 MSH6 MSH2
7 mismatched DNA binding GO:0030983 9.65 MSH6 MSH2 MLH1
8 MutLalpha complex binding GO:0032405 9.55 MUTYH MSH6 MSH2
9 oxidized purine DNA binding GO:0032357 9.43 MUTYH MSH6 MSH2
10 guanine/thymine mispair binding GO:0032137 9.1 MSH6 MSH2 MLH1

Sources for Rectum Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....